Welcome to our dedicated news page for Atossa Therapeutics (Ticker: $ATOS), a resource for investors and traders seeking the latest updates and insights on Atossa Therapeutics.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Atossa Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Atossa Therapeutics's position in the market.
Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) has fully enrolled the (Z)-endoxifen arm of the Phase 2 I-SPY 2 clinical trial, evaluating it as a neoadjuvant treatment for newly diagnosed estrogen receptor-positive invasive breast cancer. The study aims to down-stage the tumor, improve tumor resectability, and reduce breast cancer recurrence. The company looks forward to seeing data from this study in the second half of 2024. The (Z)-endoxifen arm enrolled 20 patients as part of the I-SPY 2 Endocrine Optimization Pilot Protocol (EOP).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
-
Rhea-AI Summary
Atossa Therapeutics, a clinical stage biopharmaceutical company (Nasdaq: ATOS), announces significant progress in 2023, with four Phase 2 trials investigating proprietary (Z)-endoxifen and important research with Weill Cornell Medicine. The Phase 2 Karisma-Endoxifen trial reached full enrollment in November 2023, studying the effect of (Z)-endoxifen in premenopausal women with measurable breast density.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.08%
Tags
-
Rhea-AI Summary
Dr. Steven Quay, MD, PhD discusses cost-benefit analysis, mRNA vaccines, and SARS-CoV-2 origins in a one-hour podcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
News
Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) appoints Dr. Arezoo Mirad as Senior Medical Director, aiming to accelerate the (Z)-endoxifen development program. With four ongoing Phase 2 trials and important data expected in 2024, the company anticipates improving the standard of care for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
-
Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) has reached full enrollment in the Karisma-Endoxifen clinical trial, a Phase 2 study investigating (Z)-endoxifen in premenopausal women with measurable mammographic breast density (MBD). The trial aims to measure reduction in MBD as a proxy for therapy response. The study is expected to provide data in the second half of 2024, with potential implications for breast cancer prevention and novel treatments like (Z)-endoxifen.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
-
News
Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) achieved significant enrollment milestones in ongoing Phase 2 clinical trials for (Z)-endoxifen, including a study in DCIS. The company ended Q3 2023 with $94.0 million in cash and cash equivalents. Key developments include 80% enrollment in ongoing trials, initiation of a new Phase 2 study, approval from Health Canada for a clinical trial, and a research agreement with Weill Cornell Medicine. Financial results show a decrease in operating expenses for Q3 2023 compared to Q3 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
Rhea-AI Summary
Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced the appointment of Jonathan Finn, CFA, to its board of directors. Finn brings over 25 years of financial industry experience, specializing in early to mid-stage biotech and technology companies. His appointment is expected to accelerate growth and commercialize assets, with critical data readouts expected next year. With four ongoing Phase 2 trials and a strong multi-year cash position, Atossa is well positioned to deliver on its vision of fundamentally changing the breast cancer treatment paradigm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.04%
Tags
-
Rhea-AI Summary
Quantum Leap Healthcare Collaborative (QLHC) has launched a Phase 2 platform study called RECAST DCIS to prevent the progression of DCIS to breast cancer. The study is evaluating three investigational endocrine therapy arms: (Z)-endoxifen, HAVAH T+Ai™, and ORSERDU®. The trial aims to reduce unnecessary surgeries and overtreatment of DCIS patients by offering up to six months of endocrine therapy and long-term active surveillance. Each investigational agent arm is expected to enroll up to 110 patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.99%
Tags
-
Rhea-AI Summary
Cognito Therapeutics appoints Greg Weaver as CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
Rhea-AI Summary
Dr. Steven Quay calls for nutritional guidelines for adolescent girls to reduce future breast cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
Atossa Therapeutics, Inc.
Nasdaq:ATOS
ATOS Rankings
ATOS Stock Data
190.46M
117.48M
0.06%
12.98%
8.43%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
SEATTLE
About ATOS
atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.